{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,12,31]],"date-time":"2025-12-31T09:37:23Z","timestamp":1767173843259,"version":"build-2238731810"},"reference-count":13,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2021,1,22]],"date-time":"2021-01-22T00:00:00Z","timestamp":1611273600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2021,1,22]],"date-time":"2021-01-22T00:00:00Z","timestamp":1611273600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/100004334","name":"Merck","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004334","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Reprod Health"],"published-print":{"date-parts":[[2021,12]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Objective<\/jats:title>\n                    <jats:p>Access to quality, effective lifesaving uterotonics in low and middle-income countries (LMICs) remains a major barrier to reducing maternal deaths from postpartum haemorrhage (PPH). Our objective was to assess the costs of care for women who receive different preventative uterotonics, and with PPH and no-PPH so that the differences, if significant, can inform better resource allocation for maternal health care.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>The costs of direct hospital care of women who received oxytocin or heat-stable carbetocin for prevention of PPH in selected tertiary care facilities in India, Kenya, Nigeria, and Uganda were assessed. We collected data from all women who had PPH, as well as a random sample of women without PPH. Cost data was collected for the cost of stay, PPH interventions, transfusions and medications for 2966 women. We analyzed the difference in cost of care at a facility level between women who experienced a PPH event and those who did not.<\/jats:p>\n                    <jats:p>Key findings<\/jats:p>\n                    <jats:p>The mean cost of care of a woman experiencing PPH in the study sites in India, Kenya, Nigeria, and Uganda exceeded the cost of care of a woman who did not experience PPH by between 21% and 309%. There was a large variation in cost across hospitals within a country and across countries.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion<\/jats:title>\n                    <jats:p>Our results quantify the increased cost of PPH of up to 4.1 times that for a birth without PPH. PPH cost information can help countries to evaluate options across different conditions and in the formulation of appropriate guidelines for intrapartum care, including rational selection of quality-assured, effective medicines. This information can be applied to national assessment and adaptation of international recommendations such as the World Health Organization\u2019s recommendations on uterotonics for the prevention of PPH or other interventions used to treat PPH.<\/jats:p>\n                    <jats:p>\n                      <jats:italic>Trial registration<\/jats:italic>\n                      HRP Trial A65870; UTN U1111-1162-8519; ACTRN12614000870651; CTRI\/2016\/05\/006969, EUDRACT 2014\u2013004445-26. Date of registration 14 August 2014\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Plain English summary<\/jats:title>\n                    <jats:p>Access to quality, effective lifesaving medicines in low and middle-income countries remains a major barrier to reducing maternal deaths from bleeding after childbirth. Information on to what extent treatments for bleeding increases the cost of care of women after childbirth is important for informed resource allocation.<\/jats:p>\n                    <jats:p>We collected data from all women who had bleeding after childbirth, as well as a random sample of women without bleeding in selected hospitals in India, Kenya, Nigeria, and Uganda. Cost data was collected for the cost of stay and interventions to manage bleeding for 2966 women. We compared the difference in cost of care between women who experienced a bleeding event and those who did not.<\/jats:p>\n                    <jats:p>The mean cost of care of a woman with bleeding in the study sites exceeded the cost of care of a woman who did not experience PPH by between 21% and 309%. There was a large variation in cost across hospitals within a country and across countries.<\/jats:p>\n                    <jats:p>Our results indicate an increased cost of bleeding of up to 4.1 times that for birth without bleeding. Effective prevention reduces the cost of care. Cost information can help countries to evaluate options across different conditions and in the formulation of appropriate guidelines for intrapartum care, including rational selection of quality-assured, effective medicines. This information can be applied to national assessment and adaptation of international recommendations such as the World Health Organization\u2019s recommendations on medications for the prevention of bleeding after childbirth or other interventions used to treat bleeding.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1186\/s12978-020-01063-x","type":"journal-article","created":{"date-parts":[[2021,1,22]],"date-time":"2021-01-22T01:02:58Z","timestamp":1611277378000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":9,"title":["Cost of hospital care of women with postpartum haemorrhage in India, Kenya, Nigeria and Uganda: a financial case for improved prevention"],"prefix":"10.1186","volume":"18","clinical-trial-number":[{"clinical-trial-number":"actrn12614000870651","registry":"10.18810\/anzctr"}],"author":[{"given":"Fiona","family":"Theunissen","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Isotta","family":"Cleps","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Shivaprasad","family":"Goudar","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Zahida","family":"Qureshi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Olorunfemi Oludele","family":"Owa","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kidza","family":"Mugerwa","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Gilda","family":"Piaggio","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4674-0998","authenticated-orcid":false,"given":"A. Metin","family":"G\u00fclmezoglu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Miriam","family":"Nakalembe","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Josaphat","family":"Byamugisha","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Alfred","family":"Osoti","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sura","family":"Mandeep","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Teko","family":"Poriot","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"George","family":"Gwako","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sunil","family":"Vernekar","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mariana","family":"Widmer","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2021,1,22]]},"reference":[{"key":"1063_CR1","doi-asserted-by":"publisher","first-page":"e323","DOI":"10.1016\/S2214-109X(14)70227-X","volume":"2","author":"L Say","year":"2014","unstructured":"Say L, et al. Global causes of maternal death: a WHO systematic analysi. Lancet Glob Health. 2014;2:e323\u201333.","journal-title":"Lancet Glob Health."},{"key":"1063_CR2","unstructured":"WHO. Maternal Mortality Factsheet. World Health Organization. 2018. https:\/\/www.who.int\/news-room\/fact-sheets\/detail\/maternal-mortality."},{"issue":"9516","key":"1063_CR3","doi-asserted-by":"publisher","first-page":"1066","DOI":"10.1016\/S0140-6736(06)68397-9","volume":"367","author":"KS Khan","year":"2006","unstructured":"Khan KS, et al. WHO analysis of causes of maternal death: a systematic review. Lancet. 2006;367(9516):1066\u201374.","journal-title":"Lancet."},{"issue":"9543","key":"1063_CR4","doi-asserted-by":"publisher","first-page":"1284","DOI":"10.1016\/S0140-6736(06)69381-1","volume":"368","author":"OMR Campbell","year":"2006","unstructured":"Campbell OMR, Graham WJ, on behalf of The Lancet Maternal Survival Series steering group. Strategies for reducing maternal mortality: getting on with what works. Lancet. 2006;368(9543):1284\u201399.","journal-title":"Lancet."},{"issue":"9879","key":"1063_CR5","doi-asserted-by":"publisher","first-page":"1747","DOI":"10.1016\/S0140-6736(13)60686-8","volume":"381","author":"JP Souza","year":"2013","unstructured":"Souza JP, et al. Moving beyond essential interventions for reduction of maternal mortality (the WHO Multicountry Survey on Maternal and Newborn Health): a cross-sectional study. Lancet. 2013;381(9879):1747\u201355.","journal-title":"Lancet."},{"key":"1063_CR6","unstructured":"United Nations Goal 3: Ensure healthy lives and promote well-being for all at all ages. Sustainable Development Goals. https:\/\/www.un.org\/sustainabledevelopment\/health\/. Accessed 20 Aug 2019."},{"key":"1063_CR7","volume-title":"WHO recommendations: uterotonics for the prevention of postpartum haemorrhage","author":"WHO","year":"2018","unstructured":"WHO. WHO recommendations: uterotonics for the prevention of postpartum haemorrhage. Geneva: World Health Organization; 2018."},{"key":"1063_CR8","unstructured":"WHO\/UNICEF\/UNFPA. Appropriate storage and management of oxytocin\u2014a key commodity for maternal health. 2019. https:\/\/apps.who.int\/iris\/bitstream\/handle\/10665\/311524\/WHO-RHR-19.5-eng.pdf."},{"key":"1063_CR9","doi-asserted-by":"publisher","first-page":"6","DOI":"10.1002\/psc.3082","volume":"24","author":"M Malm","year":"2018","unstructured":"Malm M, Madsen I, Kjellstr\u00f6m J. Development and stability of a heat-stable formulation of carbetocin for the prevention of postpartum haemorrhage for use in low and middle-income countries. J Peptide Sci. 2018;24:6.","journal-title":"J Peptide Sci"},{"key":"1063_CR10","doi-asserted-by":"publisher","first-page":"743","DOI":"10.1056\/NEJMoa1805489","volume":"379","author":"M Widmer","year":"2018","unstructured":"Widmer M, et al. Heat-stable carbetocin versus oxytocin to prevent hemorrhage after vaginal birth. N Engl J Med. 2018;379:743\u201352.","journal-title":"N Engl J Med"},{"key":"1063_CR11","volume-title":"The cost to the health system of postpartum hemorrhage in Egypt","author":"M Vlassoff","year":"2016","unstructured":"Vlassoff M, Abdalla HH, Gor V. The cost to the health system of postpartum hemorrhage in Egypt. New York: Guttmacher Institute; 2016."},{"issue":"13","key":"1063_CR12","doi-asserted-by":"publisher","first-page":"2076","DOI":"10.1111\/1471-0528.13998","volume":"123","author":"MR Torloni","year":"2016","unstructured":"Torloni MR, et al. Quality of oxytocin available in low- and middle-income countries: a systematic review of the literature. BJOG. 2016;123(13):2076\u201386.","journal-title":"BJOG"},{"key":"1063_CR13","unstructured":"Concept Foundation. Oxytocin quality\u2014evidence for action. Concept Foundation\u2014Resources. 2018. https:\/\/www.conceptfoundation.org\/wp-content\/uploads\/2018\/03\/Oxytocin-Quality-Evidence-for-Action.pdf. Accessed 23 Sept 2019."}],"updated-by":[{"DOI":"10.1186\/s12978-021-01110-1","type":"correction","label":"Correction","source":"publisher","updated":{"date-parts":[[2021,3,6]],"date-time":"2021-03-06T00:00:00Z","timestamp":1614988800000}}],"container-title":["Reproductive Health"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12978-020-01063-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s12978-020-01063-x\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12978-020-01063-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,8,10]],"date-time":"2021-08-10T12:38:06Z","timestamp":1628599086000},"score":1,"resource":{"primary":{"URL":"https:\/\/reproductive-health-journal.biomedcentral.com\/articles\/10.1186\/s12978-020-01063-x"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,1,22]]},"references-count":13,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2021,12]]}},"alternative-id":["1063"],"URL":"https:\/\/doi.org\/10.1186\/s12978-020-01063-x","relation":{},"ISSN":["1742-4755"],"issn-type":[{"value":"1742-4755","type":"electronic"}],"subject":[],"published":{"date-parts":[[2021,1,22]]},"assertion":[{"value":"21 April 2020","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"25 December 2020","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"22 January 2021","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"6 March 2021","order":4,"name":"change_date","label":"Change Date","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"Correction","order":5,"name":"change_type","label":"Change Type","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"A Correction to this paper has been published:","order":6,"name":"change_details","label":"Change Details","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"https:\/\/doi.org\/10.1186\/s12978-021-01110-1","URL":"https:\/\/doi.org\/10.1186\/s12978-021-01110-1","order":7,"name":"change_details","label":"Change Details","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The trial protocol was approved by the relevant ethics committees and regulatory agencies in each country, by the Special Programme of Research in Human Reproduction (HRP) research proposals review panel based at the World Health Organization (WHO) and by the WHO Ethics Review Committee.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"We declare no competing interests.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"18"}}